Literature DB >> 9737697

Schedule and concentration-dependent induction of apoptosis in leukemia cells by nitric oxide.

P J Shami1, D L Sauls, J B Weinberg.   

Abstract

Nitric oxide (NO) has potent antiproliferative properties. In previous work we have shown that NO inhibits growth, induces differentiation and modulates gene expression in acute nonlymphocytic leukemia (ANLL) cells. The goal of this work was to determine whether the rate of NO delivery affected its growth inhibition of ANLL cells. We also wanted to determine whether the NO inhibition of ANLL cell growth is associated with the induction of apoptosis. We treated HL-60 and U937 cells with three compounds that generate the same amount of NO but at different rates. MAMA-NO, PAPA-NO and DETA-NO have half-lives of NO delivery of 2 and 30 min, and 20 h, respectively. The compound with the longest t(1/2) of NO delivery (DETA-NO) was the most potent inhibitor of leukemia cell and colony growth. Furthermore, the NO-induced growth inhibition was associated with apoptosis in a rate and concentration-dependent fashion.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9737697     DOI: 10.1038/sj.leu.2401131

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  13 in total

1.  JS-K has potent anti-angiogenic activity in vitro and inhibits tumour angiogenesis in a multiple myeloma model in vivo.

Authors:  Tanyel Kiziltepe; Kenneth C Anderson; Jeffery L Kutok; Lee Jia; Kenneth M Boucher; Joseph E Saavedra; Larry K Keefer; Paul J Shami
Journal:  J Pharm Pharmacol       Date:  2010-01       Impact factor: 3.765

2.  Synthesis and in vitro anti-leukemic activity of structural analogues of JS-K, an anti-cancer lead compound.

Authors:  Harinath Chakrapani; Michael M Goodblatt; Vidya Udupi; Swati Malaviya; Paul J Shami; Larry K Keefer; Joseph E Saavedra
Journal:  Bioorg Med Chem Lett       Date:  2008-01-04       Impact factor: 2.823

3.  Anticancer potency of nitric oxide-releasing liposomes.

Authors:  Dakota J Suchyta; Mark H Schoenfisch
Journal:  RSC Adv       Date:  2017-11-20       Impact factor: 3.361

4.  Effect of a Pluronic(®) P123 formulation on the nitric oxide-generating drug JS-K.

Authors:  Imit Kaur; Ken M Kosak; Moises Terrazas; James N Herron; Steven E Kern; Kenneth M Boucher; Paul J Shami
Journal:  Pharm Res       Date:  2014-10-18       Impact factor: 4.200

Review 5.  Effects of tempol and redox-cycling nitroxides in models of oxidative stress.

Authors:  Christopher S Wilcox
Journal:  Pharmacol Ther       Date:  2010-02-11       Impact factor: 12.310

6.  Aryl bis(diazeniumdiolates): potent inducers of S-glutathionylation of cellular proteins and their in vitro antiproliferative activities.

Authors:  Daniela Andrei; Anna E Maciag; Harinath Chakrapani; Michael L Citro; Larry K Keefer; Joseph E Saavedra
Journal:  J Med Chem       Date:  2008-12-25       Impact factor: 7.446

7.  Hypoxic conditioning suppresses nitric oxide production upon myocardial reperfusion.

Authors:  Myoung-Gwi Ryou; Jie Sun; Kevin N Oguayo; Eugenia B Manukhina; H Fred Downey; Robert T Mallet
Journal:  Exp Biol Med (Maywood)       Date:  2008-04-11

8.  Gene expression profiling for nitric oxide prodrug JS-K to kill HL-60 myeloid leukemia cells.

Authors:  Jie Liu; Swati Malavya; Xueqian Wang; Joseph E Saavedra; Larry K Keefer; Erik Tokar; Wei Qu; Michael P Waalkes; Paul J Shami
Journal:  Genomics       Date:  2009-04-05       Impact factor: 5.736

9.  Synthesis, mechanistic studies, and anti-proliferative activity of glutathione/glutathione S-transferase-activated nitric oxide prodrugs.

Authors:  Harinath Chakrapani; Ravi C Kalathur; Anna E Maciag; Michael L Citro; Xinhua Ji; Larry K Keefer; Joseph E Saavedra
Journal:  Bioorg Med Chem       Date:  2008-09-30       Impact factor: 3.641

10.  Cellular distribution studies of the nitric oxide-generating antineoplastic prodrug O(2) -(2,4-dinitrophenyl)1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1,2-diolate formulated in Pluronic P123 micelles.

Authors:  Imit Kaur; Moises Terrazas; Ken M Kosak; Steven E Kern; Kenneth M Boucher; Paul J Shami
Journal:  J Pharm Pharmacol       Date:  2013-07-10       Impact factor: 3.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.